Skip to main content
S&P 5007,696.02+1.68%DOW53,299.35+2.92%NASDAQ25,806.01+1.71%BTC$80,353.00+3.61%ETH$2,423.32+5.73%GOLD$4,073.00+3.37%OIL$88.31-8.10%
Smart Investors Daily
SID Premium
HR

NASDAQ · HROW

Harrow Health, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$28.54

Up+$0.72 (+2.52%)

Updated Nov 4, 2026, 6:57 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.89B
P/E ratio
-183.74
Dividend yield
0.00%
52-week range
$26.96 – $47.50
Volume
626.13K
Avg. volume
738.98K

Price performance · HROW

HROW price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

HROW closed at $28.54 after 21 trading sessions, down 5.96% for the selected period.

Last close
$28.54
Period change
-5.96%
Period low
$27.24
Period high
$30.62
Daily close
View OHLC price history
HROW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$28.21$28.98$27.81$28.54626.13K
Nov 2, 2026$28.38$28.91$27.29$28.20742.63K
Oct 30, 2026$29.69$30.05$28.0825$28.24335.28K
Oct 29, 2026$29.90$30.28$29.6058$29.99321.08K
Oct 28, 2026$28.96$29.74$28.70$29.39327.33K
Oct 27, 2026$29.10$29.57$28.435$29.07635.45K
Oct 26, 2026$28.61$29.48$28.30$28.95499.15K
Oct 23, 2026$27.76$28.555$27.14$28.44854.71K
Oct 22, 2026$27.82$28.45$27.702$28.15440.12K
Oct 21, 2026$28.26$28.66$27.98$28.24524.42K
Oct 20, 2026$27.70$29.25$27.70$28.07526.97K
Oct 19, 2026$27.40$28.53$27.40$27.68576.13K
Oct 16, 2026$28.59$28.665$27.13$27.28560.47K
Oct 15, 2026$27.14$28.92$27.03$28.75583.47K
Oct 14, 2026$28.00$28.31$26.96$27.24660.46K
Oct 13, 2026$28.96$29.425$28.03$28.24807.08K
Oct 12, 2026$29.38$29.73$28.86$29.11577.03K
Oct 9, 2026$30.73$30.90$27.00$29.361.35M
Oct 8, 2026$30.35$31.11$30.00$30.52566.01K
Oct 7, 2026$30.09$31.11$29.90$30.62708.53K
Oct 6, 2026$30.86$30.90$29.845$30.35422K

Latest HROW news

The latest Smart Investors Daily articles mentioning HROW.

Stock researchCompany · Overview

HROW research

Overview

Company profile and research snapshot.

Company profile

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$73.00
Implied upside
—
Analysts
—
HROW recent ratings
DateFirmRatingTarget
Oct 7, 2026BTIGBuy—
Sep 9, 2026Leerink PartnersOutperform—
Aug 11, 2026BTIGBuy—
Jul 21, 2026BTIGBuy—
May 13, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

Generated Nov 4, 2026, 5:12 PM

Why Is HROW Up Today?

Harrow Health shares gained 2.04% today following announcements about the company's new HarrowRx prescribing platform and a strategic partnership with PHIL to power the solution. The developments signal management's commitment to streamlining its eye care portfolio and improving the prescriber experience through integrated technology.

    Bottom line: Today's modest rally reflects cautious optimism around Harrow's HarrowRx platform launch and PHIL partnership, which addresses a real market need for streamlined prescribing workflows. However, investors should remain vigilant about execution risks and demand concrete evidence of adoption and financial impact before drawing strong conclusions about the initiative's long-term value contribution.

    Yahoo · Nov 2, 2026

    PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio

    SCOTTSDALE, Ariz., November 02, 2026--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow’s new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow’s branded ophthalmic portfolio from one destination within the electronic medical record (EMR) systems they already use, with bui

    Yahoo · Nov 2, 2026

    Harrow Launches HarrowRx Platform

    HarrowRx to Simplify Access to Harrow Products and Integrate Into the Eyecare Practice Workflow, Providing a Single Prescribing Destination Within Existing Electronic Medical Record (EMR) SystemsNASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow’s entire portfo

    Yahoo · Oct 26, 2026

    Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026

    Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 10, 2026NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2026, on Monday, November 9, 2026, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” se

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By